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Abstract
Background: Adult-onset Still’s disease (AOSD) is a systemic inflammatory disorder of unknown aetiology usually
affecting young adults. Interestingly, recent evidence from the juvenile counterpart of AOSD suggested the
emergent high fatality rate of lung disease (LD) in these patients. In this work, we aimed to characterise LD in
AOSD, to identify associated clinical features and predictive factors, and to describe long-term outcomes of the
disease comparing patients with LD and those without.
Methods: A retrospective assessment of prospectively followed patients, from January 2001 to December 2019, was
provided to describe the rate of LD in AOSD, associated clinical features and predictive factors, and long-term
outcomes. Patients with AOSD, who were included in Gruppo Italiano di Ricerca in Reumatologia Clinica e
Sperimentale (GIRRCS) cohort, were assessed.
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Results: Out of 147 patients included in GIRRCS cohort, 18 (12.25%) patients were reported to be affected by LD, at
the time of diagnosis of AOSD, who were characterised by older age, a higher prevalence of myalgia, of lymph
node involvement, of pleuritis, and abdominal pain. Furthermore, patients with LD showed higher values of
systemic score and ferritin. Among those clinical variables, older age and systemic score were also independently
predictors of LD. Chest CT scans were also obtained, and the most common finding was the peripheral
consolidations in 8 (44.4%) patients. Finally, a higher mortality rate, of 38.9%, was registered in patients with LD
than others, since it was associated with a significant decreased survival rate.
Conclusions: The presence of LD could suggest an emergent cause of mortality in AOSD, as observed in juvenile
counterpart recognising a further marker of severity and poor prognosis to be careful evaluated. Patients with LD
were also characterised by some clinical features, higher values of systemic score and ferritin than the others,
identifying a subset of patients mostly burdened by systemic signs and symptoms. Although specific designed
future studies are needed to fully elucidate the significance of LD in AOSD, a more accurate evaluation and
management of this feature could improve the long-term outcomes of these patients.
Keywords: Adult onset Still’s disease, Lung disease, Mortality
Background
Adult-onset Still’s disease (AOSD) is a systemic inflam-
matory disorder of unknown aetiology usually affecting
young adults [1]. AOSD is multigenic autoinflammatory
disease, defined at the “crossroads” between autoinflam-
matory and autoimmune diseases due to the pathogenic
involvement of both arms of immune system [2]. Spiking
fever, arthritis, and evanescent rash are frequently ob-
served during the disease [3]. Other clinical manifestations
include sore throat, elevated liver enzymes, lymphadenop-
athy, liver involvement, splenomegaly, and serositis [3].
Laboratory tests reflect the systemic inflammatory process
showing high levels of erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP), and a typical hyperferriti-
nemia [4]. The latter, despite the poor specificity, is con-
sidered strongly suggestive of AOSD, also because of its
pathogenic role is supposed [5]. Analysing long-term out-
comes of AOSD, one third of patients would usually de-
velop a monocyclic pattern, characterised by a systemic
single episode, whereas others either a polycyclic pattern,
associated with multiple flares alternating with remissions,
or a chronic pattern, related to a persistently active disease
[6]. Concerning the therapeutic management, it is mainly
aimed at targeting pro-inflammatory signs and symptoms
of the disease; therefore, glucocorticoids (GCs), synthetic
disease-modifying anti-rheumatic drugs (DMARDs), and,
in refractory cases, biologic DMARDs, are used to treat
these patients [7–9]. However, despite these therapies, pa-
tients with AOSD may experience several flares and life-
threatening complications, leading to a mortality rate up
to 16% [10]. In fact, AOSD is burdened by severe compli-
cations, mostly macrophage activation syndrome (MAS),
which are characterised by a high mortality rate in adult
patients [11]. Interestingly, recent evidence from the ju-
venile counterpart of AOSD, the systemic-onset juvenile
idiopathic arthritis (SJIA), suggested the emergent high
fatality rate of lung disease (LD) [12, 13]. Despite this find-
ing, few studies, mainly isolated case reports, analysed LD
in AOSD so far [14–16], proposing that nearly 5% of pa-
tients with AOSD could be affected by LD, with two main
patterns, one characterised by an acute respiratory distress
syndrome (ARDS), and one with other LDs, including
bronchiolitis and nonspecific interstitial lung diseases [16].
On these bases, given the prognostic role of LD in paediat-
ric patients and the inconclusive evidence in adult ones,
we aimed to characterise LD in AOSD and to identify
associated clinical features and predictive factors. In
addition, by analysis of follow-up, we designed a long-
term evaluation to describe outcomes of the disease com-
paring patients with LD and those without.
Materials and methods
Study design, settings, and patients
A retrospective assessment of prospectively followed pa-
tients, from January 2001 to December 2019, was pro-
vided to describe the rate of LD in AOSD, associated
clinical features and predictive factors, and long-term
outcomes. Patients with AOSD, who were included in
Gruppo Italiano di Ricerca in Reumatologia Clinica e
Sperimentale (GIRRCS) cohort, were assessed. All pa-
tients fulfilled Yamaguchi’s criteria for AOSD [17]. The
local Ethics Committee (Comitato Etico Azienda Sani-
taria Locale 1 Avezzano/Sulmona/L’Aquila, L’Aquila,
Italy, protocol number 0139815/16) approved the study,
which was performed according to the Good Clinical
Practice guidelines and the Declaration of Helsinki.
Clinical variables and data sources
By analysis of the clinical charts of patients, clinical fea-
tures, systemic score, occurrence life-threatening compli-
cations, therapies, and patterns of disease were reported,
as previously detailed [10, 18]. The clinical workup before
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the AOSD diagnosis considered the exclusion of potential
mimickers. We assessed infections by blood cultures, bone
marrow cultures (in case of MAS), serology, PCR analyses,
chest X-rays, and abdominal echography. We also evalu-
ated the possible differential diagnosis with malignancies
using chest X-rays, abdominal echography, and blood
samples. Despite these exams, in the case of further suspi-
cion, we added CT and/or PET/CT exams to the diagnos-
tic workup. Thus, chest-X-rays were performed in all
patients and in those with further suspicion of pulmonary
involvement or the need to exclude infections or malig-
nancies chest CT scans were also performed. LD was de-
fined as AOSD-related parenchymal lung involvement as
reported in available literature [12, 13, 16]. In patients
with suspicion of LD, chest CT scan was performed, and
findings codified according to available literature [12, 13]
in different main patterns: (i) multilobar, predominantly
peripheral septal thickening, parahilar, and/or anterior
upper lobes with or without adjacent ground glass opaci-
ties; (ii) crazy-paving; (iii) peripheral consolidations; (iv)
peribronchovascular consolidations; (v) predominantly
ground-glass opacities [12, 13]. Crazy paving was referred
to the appearance of ground-glass opacity with superim-
posed interlobular septal thickening and intralobular sep-
tal thickening, seen on chest CT. Before diagnosing LD
related to AOSD, all other possible mimickers were ex-
cluded, with more attention to the infectious diseases, as
previously performed in SIJA and AOSD [10, 12, 13, 18].
Furthermore, the occurrence of MAS and other AOSD
life-threatening complications were assessed, as previously
reported [19–21]. Patients in remission were defined as
those achieving a complete disappearance of any clinical
Table 1 Descriptive statistics of clinical characteristics of assessed patients with AOSD and grouped according to the presence of LD
Clinical characteristics 18 patients with LD 129 patients without LD P values, patients with LD vs
patients without LD
Age, mean ± SD 53.6 ± 14.7 years 44.0 ± 16.1 years 0.017
Gender, n (%) 9 (50.0) male 80 (62.0) male 0.441
Fever, n (%) 18 (100.0) 129 (100.0) /
Arthritis, n (%) 16 (88.9) 114 (88.4) 0.654
Skin Rash, n (%) 13 (72.2) 97 (75.2) 0.492
Myalgia, n (%) 16 (88.9) 79 (61.2) 0.033
Splenomegaly, n (%) 14 (77.8) 84 (65.1) 0.215
Lymph node involvement, n (%) 14 (77.8) 66 (51.2) 0.028
Sore throat, n (%) 12 (66.7) 71 (55.0) 0.450
Liver Involvement, n (%) 11 (61.1) 80 (62.0) 0.567
Pleuritis, n (%) 10 (55.5) 19 (14.7) < 0.001
Pericarditis, n (%) 7 (38.9) 24 (18.6) 0.064
Abdominal Pain, n (%) 8 (44.4) 12 (9.3) 0.001
Systemic score, mean ± SD 8.4 ± 2.1 5.7 ± 1.8 < 0.001
MAS, n (%) 5 (27.8) 21 (16.3) 0.071
Leucocytosis > 15,000/mm3, n (%) 11 (61.1) 67 (51.9) 0.318
ESR, mean ± SD 70.7 ± 24.7 mm/hr 69.2 ± 27.7 mm/hr 0.821
CRP, median (interquartile range) 113.1 (99.2) mg/L 77.0 (79.6) mg/L 0.080
Ferritin, median (interquartile range) 3370.5 (3051.8) ng/mL 2841.5 (3545.1) ng/mL 0.010
Low dosage GCs (≤ 0.5 mg/kg/day), n (%) 4 (22.2) 57 (44.2) 0.062
High dosage GCs (> 0.5 mg/kg/day), n (%) 14 (77.8) 72 (55.8) 0.789
Synthetic DMARDs, n (%) 11 (61.1) 84 (65.1) 0.464
Biologic DMARDs, n (%) 5 (27.8) 39 (30.2) 0.536
Monocyclic disease pattern, n (%) 4 (22.2) 47 (36.4) 0.510
Polycyclic disease pattern, n (%) 3 (16.7) 46 (35.6) 0.044
Chronic disease pattern, n (%) 4 (22.2) 34 (26.3) 0.479
Mortality, n (%) 7 (38.9) 13 (10.1) 0.004
Time of follow-up, median (interquartile range) 2.8 (3.4) years 3.9 (3.4) years 0.199
MRI magnetic resonance imaging, AOSD adult onset Still’s disease, n number of patients, DMARDs disease-modifying anti-rheumatic drugs, MAS macrophage
activation syndrome, ESR erythrocyte sedimentation rate, CRP C-reactive protein, GCs glucocorticoids. Bolded values are statistically significant (p < 0.05)
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and laboratory feature of the disease. Inflammatory
markers, including ESR, CRP, and ferritin were recorded.
At the end of follow-up, patients were categorised into
three different disease courses, monocyclic, polycyclic, and
chronic patterns, as previously performed [10]. The ad-
ministration of therapies, glucocorticoids (GCs), synthetic,
and biologic DMARDs, for managing AOSD was also reg-
istered and categorised, at the time of diagnosis and dur-
ing the follow-up, as already done [22, 23].
Statistical methods
Statistics firstly provided the descriptive analysis, and
collected results were presented as mean and standard
deviation (SD) or median and interquartile range (IQR)
according to their distribution. Clinical characteristics of
patients with and without LD were compared by para-
metric or non-parametric t tests for all the continuous
variables, and chi-squared test was used for the categorical
ones, as appropriate. Possible correlations among the pres-
ence of LD and ESR, CRP, ferritin, and systemic score
were estimated by using a point-biserial coefficient correl-
ation. Furthermore, regression analyses were performed to
assess possible predictive factors of LD presence. Kaplan-
Meier curves were plotted to determine the rates of
survival of patients with AOSD with and without LD; the
difference between curves was determined by the log-rank
(Mantel-Cox) test. Additionally, Cox regression analysis
for survival was performed to evaluate the role of LD on
mortality of those patients. Due to the relatively simple
study design, few retrieved missing data were managed by
exclusion of these from analyses. Two-sided P values <
0.05 were considered as being statistically significant. The
Statistics Package for Social Sciences (SPSS for Windows,
version 17.0, SPSS Inc., Chicago, IL, USA) was used for all
analyses.
Results
Clinical characteristics of patients with LD
Out of 147 patients included in GIRRCS cohort, 18
(12.25%) patients were reported to be affected by LD, at
the time of diagnosis of AOSD. Out of these 18 patients,
8 (44.44%) reported smoking habit, presently or formerly.
As detailed in Table 1, these patients were characterised
by older age (p = 0.017), a higher prevalence of myalgia
(p = 0.033), of lymph node involvement (p = 0.028), of
pleuritis (p < 0.001), and abdominal pain (p = 0.001).
Furthermore, patients with LD showed higher values of
systemic score (p < 0.001) and ferritin (p = 0.010). In
fact, systemic score (coefficient 0.347, p < 0.001) and
ferritin (coefficient 0.148, p = 0.031) were significantly
correlated with LD, whereas ESR (coefficient 0.014, p =
0.843) and CRP (coefficient 0.084, p = 0.220) did not. In
patients with LD, respiratory signs and symptoms were
mostly subtle, including mild tachypnoea, dyspnoea,
and chronic cough, with a discrepancy between clinical
picture and extension of lung involvement. The most
common CT finding was the peripheral consolidations
in 8 (44.4%) patients, less frequently peribronchovascu-
lar consolidations in 4 patients (22.2%), predominantly
ground glass opacities in 3 patients (16.7%), crazy-
paving in 3 patients (16.7%), and multilobar predomin-
antly peripheral septal thickening in 2 patients (11.1%).
Fig. 1 In this figure, different radiological features of LD, present at the same time, in a patient with AOSD are shown as follows: a crazy paving
(white arrow), b crazy paving (white arrow), c peribronchovascular consolidations with ground glass, and d peripheral consolidation
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Most showed one or more of these patterns, which ap-
peared to be not mutually exclusive. In almost all pa-
tients, 14 out of 18 (77.8%), a follow-up evaluation of
chest CT scan was retrieved, but analysed without any
inferential analysis due to the lack of power. In patients,
who improved, a complete disappearance of inflamma-
tory findings was reported, whereas in others a worsen-
ing of LD was observed. In Fig. 1, representative images
of chest CT findings of LD related AOSD are shown,
whereas in Fig. 2, disappearance or worsening of in-
flammatory signs are reported after therapy. In these
patients, no evidence of clinical pulmonary hyperten-
sion, of ARDS, and clubbing was reported. Finally, un-
usual adverse drug reactions were not retrieved.
Predictive factors of LD
Considering the prognostic role of LD presence, at the
time of diagnosis, possible predictive factors of this
feature were tested. By univariate analyses, age (OR =
1.04, 95%CI = 1.01–1.07, p = 0.021), myalgia (OR =
5.06, 95%CI = 1.12–22.97, p = 0.036), lymph node in-
volvement (OR = 3.34, 95%CI = 1.04–10.69, p = 0.042),
pleuritis (OR = 7.34, 95%CI = 2.53–20.67, p < 0.001),
abdominal pain (OR= 7.80, 95%CI = 2.59–23.51, p < 0.001),
and systemic score (OR = 2.14, 95%CI = 1.54–2.97,
p < 0.001) were retrieved to be significantly predict-
ive on the likelihood of LD presence. Based on the
results of univariate analyses, a multivariate regression
model was built to evaluate the independent predict-
ive role of selected variables (age and systemic score)
on the likelihood of LD presence, at the time of diag-
nosis (Table 2). Despite the significant results of univariate
analyses, we selected the systemic score to be added in the
multivariate analysis since including all other clinical vari-
ables and due to the low number of patients with LD. The
multivariate analysis showed that older age (OR = 1.04,
95%CI 1.01–1.08, p = 0.044) and systemic score (OR =
2.08, 95%CI = 1.50–2.88, p < 0.001) were independently
predictors on the likelihood of LD presence. Considering
the reported prognostic role of systemic score ≥ 7 on
Fig. 2 In this figure, radiological features of LD, in patients with AOSD, before and after therapies are shown. In panel a, a peribronchovascular
consolidation is shown (white arrow) which is completely disappeared after therapy with high dosage of GCs, as shown in panel b. In panel d,
the occurrence of ground glass opacities is reported, after previous negative findings, as shown in panel c. In panel f, the occurrence of
peripheral consolidations (white arrows) with concomitant pleural effusion (black arrow) is reported, after previous negative findings, as shown in
panel e
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mortality in AOSD [10], we tested systemic score also as
dichotomy (“yes systemic score ≥ 7”/“no systemic score ≥
7). Systemic score ≥ 7 resulted to be a significant predictor
on the likelihood of LD presence, in univariate analysis
(OR = 19.16, 95%CI = 4.20–87.41, p < 0.001) as well as in
multivariate analysis (OR = 23.31, 95%CI = 4.85–42.08,
p < 0.001).
Survival rate of patients with LD
A higher mortality rate (p = 0.004), of 38.9%, was regis-
tered in patients with and LD than the others. In these
patients, no specific chest CT scan pattern was retrieved.
Specifically, 5 patients died from uncontrollable MAS, 1
from multiple organ failure with the liver and kidney
failures, and 1 from severe infection related to the im-
munosuppressive therapy, whereas no death due to
ARDS was registered in our cohort. The presence of LD,
at the time of diagnosis, was significantly associated with
a decreased survival rate of patients (p < 0.001) during
the follow-up, as shown in Fig. 3. Furthermore, the pres-
ence of LD, at the time of diagnosis, significantly pre-
dicted the mortality in both univariate (HR = 4.81,
95%CI = 1.91–12.12, p = 0.001) and in age- and gender-
adjusted multivariate (HR = 3.41, 95%CI = 1.28–9.12, p =
0.014) analyses for survival.
Discussion
In the present evaluation, the assessment of LD was per-
formed in a large cohort of patients with AOSD, analys-
ing associated clinical characteristics, predictive factors,
and long-term outcomes. Patients with LD were
characterised by some clinical features, higher values of
systemic score and ferritin, than those without.
Some clinical variables, older age and systemic score,
were retrieved to be clinical independent predictors on
the likelihood of LD presence. Analysing the follow-up,
a higher mortality rate was observed in patients with LD,
thus identifying an additional marker of severity and
poor prognosis to be careful evaluated in AOSD.
In this cohort, 12.25% of patients with AOSD were
reported to be affected by LD. This result could suggest
a higher rate than reported in available literature [16],
but it must be pointed out that mainly isolated case re-
ports investigated this issue [14–16], thus limiting the
validity of this estimation in adults. Clinically, as ob-
served in SJIA, patients with AOSD-related LD showed
a striking dissociation between relatively subtle clinical
features, including mild tachypnoea, dyspnoea, chronic
cough, and the extension of the inflammatory process
in lungs based on chest CT. Furthermore, patients with
LD were characterised by a higher prevalence of
myalgia, of lymph node involvement, of pleuritis, and
abdominal pain, than others. In addition, those patients
showed higher values of systemic score and ferritin.
Except from the higher levels of ferritin, different clin-
ical characteristics were retrieved comparing patients
with LD with either SIJA or AOSD [12, 13]. In fact, we
did not observe any evidence of clinical pulmonary
hypertension, of ARDS, clubbing, and unusual adverse
drug reactions. In spite of a continuum of the disease is
proposed between paediatric and adult patients [24],
some dissimilarities, from both clinical and pathogenic
Table 2 Regression analyses of predictive factors on the
likelihood of LD presence in AOSD
Clinical variables OR 95%CI p
Univariate analyses
Age 1.04 1.01–1.07 0.021
Male gender 0.61 0.23–1.65 0.332
Arthritis 1.05 0.22–5.04 0.95
Skin Rash 0.86 0.28–2.59 0.786
Myalgia 5.06 1.12–22.97 0.036
Splenomegaly 1.87 0.58–6.03 0.290
Lymph node involvement 3.34 1.04–10.69 0.042
Sore throat 1.63 0.58–4.62 0.355
Liver Involvement 0.96 0.35–2.65 0.941
Pleuritis 7.34 2.53–20.67 < 0.001
Pericarditis 2.78 0.98–7.92 0.060
Abdominal pain 7.80 2.59–23.51 < 0.001
Systemic score 2.14 1.54–2.97 < 0.001
Systemic score≥ 7 19.16 4.20–87.41 < 0.001
MAS 1.39 0.42–4.62 0.592
Leucocytosis > 15,000/mm3 1.45 0.53–3.99 0.467
ESR 1.01 0.98–1.02 0.819
CRP 1.32 0.85–2.06 0.214
Ferritin 1.48 0.95–2.31 0.083
Low dosage of GCs 0.36 0.11–1.16 0.086
Synthetic DMARDs 0.84 0.30–2.32 0.739
Biologic DMARDs 0.88 0.29–2.66 0.831
Monocyclic Pattern 0.87 0.31–2.48 0.798
Polycyclic disease pattern 0.23 0.05–1.02 0.064
Chronic disease pattern 0.80 0.25–2.59 0.708
Multivariate analyses
Age 1.04 1.01–1.08 0.044
Systemic score 2.08 1.50–2.88 < 0.001
X2 = 28.72, p < 0.001
Age 1.05 1.01–1.09 0.011
Systemic score≥ 7 23.31 4.85–42.08 < 0.001
X2 = 23.06, p < 0.001
MRI magnetic resonance imaging, AOSD adult onset Still’s disease, ESR
erythrocyte sedimentation rate, CRP C-reactive protein, GCs glucocorticoids,
DMARDs disease-modifying anti-rheumatic drugs. Bolded values are statistically
significant (p < 0.05)
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point of views, are reported [25–27], suggesting the
need of further studies, specifically designed and ad-
equately powered, to fully investigate this issue. In the
present evaluation, findings of chest CT scan were ana-
lysed and the most common pattern was the peripheral
consolidations in 44.4% of patients, differently from
what observed in paediatric patients [12, 13].
Furthermore, despite the lack of power, the results
about chest CT scans, which were obtained after the
therapies, suggested that LD could also follow the activ-
ity of the disease, reducing or enhancing according to
the achievement of remission or not. Analysing predict-
ive factors of LD, at the time of diagnosis, older age, and
higher systemic score resulted to be independent predic-
tors of LD in AOSD. The predictive role of older age
seems to be conflicting with findings on paediatric ages,
possibly suggesting the role of environmental or occupa-
tional factors, such as smoking history or specific dietary
habit, to be studied in worsening the course of the dis-
ease. Systemic score is a prognostic clinical tool which
may be applied to patients with AOSD, identifying, at
the time of diagnosis, those patients with the likelihood
of a more severe outcome [10]. In addition, a cut-off at
7.0 of the systemic score would identify those patients at
higher risk of AOSD-related death, confirming that the
multi-organ involvement at the time of diagnosis is a
predictive factor of a more severe outcome and in-
creased mortality [10, 25]. Taking together all these fea-
tures about LD in AOSD, a subset of patients could be
identified, mostly characterised by a systemic signs and
symptoms of the disease.
Analysing the follow-up of these patients, the presence
of LD reduced the survival rate of patients with AOSD,
since associated with about 40% of mortality, mirroring
what observed in SJIA [12, 13, 28, 29], and suggesting a
careful evaluation of this feature. In these patients, no
specific chest CT scan pattern was retrieved, suggesting
that further studies are needed to fully elucidate this
issue. The higher mortality rate observed in our study
did not confirm results from other European AOSD
series [30, 31], but paralleled with data reported on Asi-
atic populations [32, 33]. In patients with LD, the main
cause of death was the occurrence of uncontrollable
MAS and not the occurrence of ARDS. This result mir-
rored the association between LD and MAS reported in
SJIA [12, 13]. In those patients, it has been suggested
that the lung involvement may trigger the systemic in-
flammation and the development of this hyperinflamma-
tory complication [34, 35]. In this context, the IFN-γ
may play a central pathogenic role. In fact, in biopsies of
lung in patients with SIJA, the analysis of expressed
genes revealed that many of the upregulated targets were
Fig. 3 Kaplan-Meier curves of survival in patients with or without LD. The presence of LD was significantly associated with a decreased survival
rate of patients with AOSD (p < 0.001)
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in gene pathways related to the IFN-γ response, includ-
ing HLA–D family members and other IFN-related
genes [13]. Furthermore, two of the most highly upregu-
lated non-HLA genes were CXCL9 and CXCL10 [13],
IFN-induced chemokines strongly correlated with the
occurrence of MAS [36, 37]. In addition, the lung is one
of the major physiological producers of IL-1 and IL-6,
which are also involved in pathogenic steps leading to
occurrence of MAS [34, 35, 38, 39]. Thus, it is possible
to suggest that the lung involvement observed in these
patients, either SIJA or AOSD, could act as a trigger to
excessively amplify the immune response, leading to a
massive release of pro-inflammatory mediators and, fi-
nally, to the occurrence of MAS.
Despite providing an analysis of LD in AOSD, the
present evaluation is affected by different limitations as-
sociated with the retrospective design, which is affected
by different biases. In addition, due to the retrospective
design, we did not have contrast enhancement CT scan
and lung biopsies, as in paediatric patients [12, 13]. Fur-
thermore, considering the retrospective design and the
discrepancy between subtle symptoms and the extension
of LD, it is also possible that the first line assessment
with chest X-rays could have miss a percentage of pa-
tients by minimal pulmonary symptoms. However, al-
though our results should be carefully generalised, it
must be pointed out that the rarity of AOSD would
make difficult to arrange prospective studies. This is a
common unmet need when dealing with rare diseases
[40, 41], thus suggesting the significance of retrospective
studies to identify relevant clinical features in generating
hypotheses to be subsequently investigated and confirmed.
Conclusions
In conclusion, the presence of LD could suggest an
emergent cause of mortality in AOSD, as observed in
SJIA, recognising a further marker of severity and poor
prognosis to be careful evaluated. Patients with LD were
also characterised by some clinical features, higher
values of systemic score and ferritin than the others,
identifying a subset of patients mostly burdened by sys-
temic signs and symptoms. Although specific designed
future studies are needed to fully elucidate the signifi-
cance of LD in AOSD, a more accurate evaluation and
management of this feature could improve the long-
term outcomes of these patients.
Abbreviations
AOSD: Adult-onset Still’s disease; ESR: Erythrocyte sedimentation rate; CRP: C-
reactive protein; GCs: Glucocorticoids; DMARDs: Disease-modifying anti
rheumatic drugs; MAS: Macrophage activation syndrome; SJIA: Systemic-
onset juvenile idiopathic arthritis; LD: Lung disease; ARDS: Acute respiratory
distress syndrome; GIRRCS: Gruppo Italiano di Ricerca in Reumatologia Clinica
e Sperimentale; SD: Standard deviation; IQR: Interquartile range
Acknowledgements
The authors thank Mrs. Federica Sensini for her technical assistance.
Authors’ contributions
All authors made substantial contributions to the conception or design of
the work, the acquisition, and interpretation of data. All authors contributed
to the critical review and revision of the manuscript and approved the final
version. All the authors agreed to be accountable for all aspects of the work.
Funding
No funding for this study.
Availability of data and materials
All data relevant to the study are included in the article.
Ethics approval and consent to participate
The local Ethics Committee (Comitato Etico Azienda Sanitaria Locale 1
Avezzano/Sulmona/L’Aquila, L’Aquila, Italy, protocol number 0139815/16)
approved the study, which was performed according to Good Clinical
Practice guidelines and the Declaration of Helsinki. After approval of our
ethic committee, we collected written informed consents for patients
presently and actively followed-up in each centre for the use of de-identified
clinical and laboratory data and images for study purposes. However, since
the retrospective nature of the study, for those patients who were not anymore
followed-up (lost to follow-up or died during the time-period of assessment),
after having made every reasonable effort to contact them, we used the fully
anonymized clinical data according to the Italian Law on privacy only for
research purposes without any other intended aim (Garante per la
protezione dei dati personali, Autorizzazione n. 9/2016 - Autorizzazione
generale al trattamento dei dati personali effettuato per scopi di ricerca
scientifica - 15 dicembre 2016 [5805552]).
Consent for publication
Not applicable, all the patients’ data are de-identified.
Competing interests
The authors declare that they have no conflicts of interest for this work.
Author details
1Rheumatology Unit, Department of Biotechnological and Applied Clinical
Sciences, University of L’Aquila, delta 6 building, PO box 67100, L’Aquila, Italy.
2Rheumatology Section, Department of Precision Medicine, University of
Campania “Luigi Vanvitelli”, Naples, Italy. 3Rheumatology Unit, Department of
Clinical Medicine and Surgery, School of Medicine, University of Naples
Federico II, Naples, Italy. 4Department of Experimental and Clinical Medicine,
University of Firenze, Florence, Italy. 5Department of Health Sciences,
University of Catanzaro “Magna Graecia”, Catanzaro, Italy. 6Rheumatology
Unit, Department of Medical and Surgery Sciences, University of Foggia,
Foggia, Italy. 7Rheumatology Unit, Department of Clinical and Experimental
Medicine, University of Messina, Messina, Italy. 8Rheumatic and Systemic
Autoimmune Diseases Unit, Department of Biomedical Sciences and Human
Oncology (DIMO), University of Bari Medical School, Bari, Italy. 9Department
of Health Promotion, Mother and Child Care, Internal Medicine and Medical
Specialties, Rheumatology section, University of Palermo, Palermo, Italy.
10Diagnostic and Interventional Radiology, Department of Biotechnological
and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy.
Received: 11 March 2020 Accepted: 12 June 2020
References
1. Ruscitti P, Giacomelli R. Pathogenesis of adult onset still’s disease: current
understanding and new insights. Expert Rev Clin Immunol. 2018;14:65–976.
2. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still’s disease.
Autoimmun Rev. 2014;13:708–22.
3. Fautrel B. Adult onset Still’s disease. Best Pract Res Clin Rheumatol. 2008;22:
773–92.
4. Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-
onset Still’s disease. Nat Rev Rheumatol. 2018;14:603–18.
5. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y.
The hyperferritinemic syndrome: macrophage activation syndrome, Still’s
Ruscitti et al. Arthritis Research & Therapy          (2020) 22:151 Page 8 of 9
disease, septic shock and catastrophic antiphospholipid syndrome. BMC
Med. 2013;11:185.
6. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult
onset Still’s disease. J Autoimmun. 2018;93:24–36.
7. Li S, Zheng S, Tang S, Pan Y, Zhang S, Fang H, Qiao J. Autoinflammatory
pathogenesis and targeted therapy for adult-onset Still’s disease. Clin Rev
Allergy Immunol. 2020;58:71–81.
8. Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an
old new drug in autoimmune disease. Expert Rev Clin Immunol. 2014;10:
1519–30.
9. Ruscitti P, Ursini F, Cipriani P, De Sarro G, Giacomelli R. Biologic drugs in
adult onset Still’s disease: a systematic review and meta-analysis of
observational studies. Expert Rev Clin Immunol. 2017;13:1089–97.
10. Ruscitti P, Cipriani P, Masedu F, Iacono D, Ciccia F, Liakouli V, et al. Adult-
onset Still’s disease: evaluation of prognostic tools and validation of the
systemic score by analysis of 100 cases from three centers. BMC Med. 2016;
14:194.
11. Ruscitti P, Cipriani P, Ciccia F, Masedu F, Liakouli V, Carubbi F, et al.
Prognostic factors of macrophage activation syndrome, at the time of
diagnosis, in adult patients affected by autoimmune disease: analysis of 41
cases collected in 2 rheumatologic centers. Autoimmun Rev. 2017;16:16–21.
12. Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K,
et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann
Rheum Dis. 2019;0:1–10.
13. Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, et al. Systemic
juvenile idiopathic arthritis-associated lung disease: characterization and risk
factors. Arthritis Rheumatol. 2019;71:1943–54.
14. Sato H, Yokoe I, Nishio S, Onishi T, Takao T, Kobayashi Y, et al. A case of
adult onset Still’s disease complicated with cryptogenic organizing
pneumonia. Intern Med. 2011;50:247–51.
15. Ak O, Ozer S, Cağ Y, Karagöz G. An adult onset Still’s disease mimicking
pneumonia. Rheumatol Int. 2012;32:2539–41.
16. Gerfaud-Valentin M, Cottin V, Jamilloux Y, Hot A, Gaillard-Coadon A, Durieu
I, et al. Parenchymal lung involvement in adult-onset still disease: a STROBE-
compliant case series and literature review. Medicine. 2016;95(30):e4258.
17. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi
H, et al. Preliminary criteria for classification of adult Still’s disease. J
Rheumatol. 1992;19:424–30.
18. Ruscitti P, Iacono D, Ciccia F, Emmi G, Cipriani P, Grembiale R, et al.
Macrophage activation syndrome in patients affected by adult onset Still’s
disease: analysis of survival rate and predictive factors in GIRRCS (Gruppo
Italiano di Ricerca in Reumatologia Clinica e Sperimentale) cohort. J
Rheumatol. 2018;45:864–72.
19. Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of adult-
onset Still’s disease. Clin Rheumatol. 2014;33:305–14.
20. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al.
Development and validation of the HScore, a score for the diagnosis of
reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66:2613–20.
21. Batu ED, Erden A, Seyhoğlu E, Kilic L, Büyükasık Y, Karadag O, et al.
Assessment of the HScore for reactive haemophagocytic syndrome in
patients with rheumatic diseases. Scand J Rheumatol. 2017;46:44–8.
22. Ruscitti P, Cipriani P, Liakouli V, Guggino G, Carubbi F, Berardicurti O, et al.
Managing adult-onset Still’s disease: the effectiveness of high-dosage of
corticosteroids as first-line treatment in inducing the clinical remission.
Results from an observational study. Medicine (Baltimore). 2019;98:e15123.
23. Ruscitti P, Cipriani P, Liakouli V, Iacono D, Pantano I, Caso F, et al.
Prescribing motivations and patients’ characteristics related to the use of
biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-
life” cohort. Rheumatol Int. 2020;40:107–13.
24. Nirmala N, Brachat A, Feist E, Blank N, Specker C, Witt M, et al. Gene-
expression analysis of adult-onset Still’s disease and systemic juvenile
idiopathic arthritis is consistent with a continuum of a single disease entity.
Pediatr Rheumatol Online. 2015;13:50.
25. Ruscitti P, Rago C, Breda L, Cipriani P, Liakouli V, Berardicurti O, et al.
Macrophage activation syndrome in Still’s disease: analysis of clinical
characteristics and survival in paediatric and adult patients. Clin Rheumatol.
2017;36:2839–45.
26. Pay S, Türkçapar N, Kalyoncu M, Simşek I, Beyan E, Ertenli I, et al. A
multicenter study of patients with adult-onset Still’s disease compared with
systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25:639–44.
27. Inoue N, Shimizu M, Tsunoda S, Kawano M, Matsumura M, Yachie A.
Cytokine profile in adult-onset Still’s disease: comparison with systemic
juvenile idiopathic arthritis. Clin Immunol. 2016;169:8–13.
28. Athreya BH, Doughty RA, Bookspan M, Schumacher HR, Sewell EM, Chatten
J. Pulmonary manifestations of juvenile rheumatoid arthritis:a report of eight
cases and review. Clin Chest Med. 1980;1:361–74.
29. Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, et al.
Pulmonary hypertension and other potentially fatal pulmonary
complications in systemic juvenile idiopathic arthritis. Arthritis Care Res
(Hoboken). 2013;65:745–52.
30. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al.
Adult-onset still disease: manifestations, treatment, outcome, and
prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91–9.
31. Kalyoncu U, Solmaz D, Emmungil H, Yazici A, Kasifoglu T, Kimyon G, et al.
Response rate of initial conventional treatments, disease course, and related
factors of patients with adult-onset Still's disease: data from a large
multicenter cohort. J Autoimmun. 2016;69:59–63.
32. Kim HA, Sung JM, Suh CH. Therapeutic responses and prognosis in adult-
onset Still’s disease. Rheumatol Int. 2012;32:1291–8.
33. Zeng T, Zou YQ, Wu MF, Yang CD. Clinical features and prognosis of adult-
onset Still’s disease: 61 cases from China. J Rheumatol. 2009;36:1026–31.
34. Ruscitti P, Cipriani P, Di Benedetto P, Liakouli V, Carubbi F, Berardicurti O,
et al. Advances in immunopathogenesis of macrophage activation
syndrome during rheumatic inflammatory diseases: toward new therapeutic
targets? Expert Rev Clin Immunol. 2017;13:1041–7.
35. Ruscitti P, Cipriani P, Di Benedetto P, Liakouli V, Berardicurti O, Carubbi F,
et al. H-ferritin and proinflammatory cytokines are increased in the bone
marrow of patients affected by macrophage activation syndrome. Clin Exp
Immunol. 2018;191:220–8.
36. Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G,
et al. Elevated circulating levels of interferon-γ and interferon-γ-induced
chemokines characterise patients with macrophage activation syndrome
complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76:
166–72.
37. Liu Y, Lightfoot YL, Seto N, Carmona-Rivera C, Moore E, Goel R, et al.
Peptidylarginine deiminases 2 and 4 modulate innate and adaptive immune
responses in TLR-7–dependent lupus. JCI Insight. 2018;3:124729.
38. GTEx Consortium. The genotype-tissue expression (GTEx) pilot analysis:
multitissue gene regulation in humans. Science. 2015;348:648–60.
39. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the
era of biologic therapy. Nat Rev Rheumatol. 2016;12:259–68.
40. Giacomelli R, Afeltra A, Alunno A, Baldini C, Bartoloni-Bocci E, Berardicurti O,
et al. International consensus: what else can we do to improve diagnosis
and therapeutic strategies in patients affected by autoimmune rheumatic
diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis,
systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s
syndrome)?: the unmet needs and the clinical grey zone in autoimmune
disease management. Autoimmun Rev. 2017;16:911–24.
41. Giacomelli R, Afeltra A, Alunno A, Bartoloni-Bocci E, Onorina Berardicurti O,
Bombardieri M, et al. Guidelines for biomarkers in autoimmune rheumatic
diseases - evidence based analysis. Autoimmun Rev. 2019;18:93–106.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Ruscitti et al. Arthritis Research & Therapy          (2020) 22:151 Page 9 of 9
